U.S. Markets closed

Tenax Therapeutics, Inc. (TENX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.8600-0.0200 (-1.06%)
At close: 4:00PM EDT
Sign in to post a message.
  • D
    DH
    Any guess on when more clinical information will be released? Need some good news!
  • O
    OnlytheNobleShallPass
    The funding is $10M of the $30M - $35M needed to get to production (their number from an earlier communication). The announced deal represents about a 7-8% dilution in share price. It does solve the immediate money issue and gives them about a year to figure out the rest of the business plan. It is a good step.

    Don't think we retail investors can look for much appreciation in the SP until the rest of the funding is figured out and sales plan is put together. I'm thinking the SP trading range will be between $1.80 and $2.50 in the near term----- this is a back of the envelope estimate that takes into account dilution and the typical SP fluctuations we have observed.
  • B
    Bill
    Looks like they finally got the funding they needed, and with a lot of upcoming publications due out, let’s hope this can finally come close to its $5 price target
  • O
    OnlytheNobleShallPass
    Just checking in -- 70 trading days left till 9/30/21, the date TENX indicated that they will run out of operating funds. Have I missed any updates that will push out this date?
  • J
    Jon Henry
    What's going on with this stock in the AH's? It closed flat during regular trading, but is up 20%+ on heavy volume in the after hours, any comments?
  • B
    Bill
    The paragraph below is the reason I’m not selling (even though I’m green) and why I believe other investors/insiders haven’t sold over the past few months. It’s a good sign when the CEO says to expect important news regarding their lead drugs as they go into PH3.

    "Our inclusion in the Russell Microcap Index comes at an exciting time for our company, as we expect to advance our two lead drug development programs (imatinib and levosimendan) towards Phase 3 clinical trials", said Anthony DiTonno, Chief Executive Officer of Tenax Therapeutics. "Over the next several months, we also anticipate a series of important research publications that will support Tenax’s pioneering approach towards the treatment of Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction.
    Bullish
  • O
    OnlytheNobleShallPass
    retail investors are not selling, however the hedge funds are. that is not a good sign. think we are headed sub two dollars again.
  • F
    Francis
    of course yes: they can make a PR regarding the ph3 clinical trial design, about the formulation of imatinib, etc
  • A
    Aaron
    Since we're all waiting, does anyone want to send out for pizza
  • B
    Bill
    Shareholders just won’t sell no matter how hard shorts try to manipulate this. Just look at the volume

    This seems like it’s going to explode any day now.

    Good luck longs
  • O
    OnlytheNobleShallPass
    Looked at the calendar and there are 84 trading days remaining until the end of 3Q2021. That is when TENX indicated they run out of money to operate. The SP still does not reflect the impact of the fund raising that will need to occur.

    Given the timeframe it looks more and more like they intend to go it alone -- there has been no mention of outside help to find a partner or acquire someone. If they were investigating partners, that would be a really good thing to share with shareholders.

    Going it alone will mean some kind of dilution.

    If anybody from TENX reads these boards, it would be good to communicate your plan for continued funding.
  • O
    OnlytheNobleShallPass
    As expected TENX announced that they have enough cash to operate through 3Q2021. A while ago they indicated about $30-35M would be needed to get their product into production. Going forward, there are two general paths that they could take: 1. some form of issuing new shares (will be dilutive and negatively impact share price; 2. Merge or sell to a suitor that will fund the rest of their excellent drug. Think there is an equal chance of either path. I'm still on the sidelines and looking for indications of which way they are leaning .Just my opinion. GLTA!!
    Neutral
  • O
    OnlytheNobleShallPass
    Noticed that Yahoo has TENX as bullish across the board. Don't think the known headwinds justify that optimism. A news release that supported the bullish indicators would be very helpful.
  • D
    DH
    Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Tenax Therapeutics, Inc - TENX What is this!?!
  • O
    OnlytheNobleShallPass
    Looks like reality is starting to sink in. TENX is a long way from sustaining a SP above $2.

    Do think there will be someone who will make a big buy and cause a momentary price jump.

    At the present, this seems like a stock to rent for a short while.

    GLTA!!
  • N
    Naor
    its only 50 mil market cap what can happen.?
    Bullish
  • O
    OnlytheNobleShallPass
    Yep - a head fake. It seems to do this every 8-10 weeks then goes back into hibernation.
  • B
    Bill
    Pre-market is a joke. 1K volume by shorts hoping to induce some opening bell panic sells

    Anyways, what happened yesterday was interesting. Someone paid a premium to buy a few hundred K shares prior to close. Hopefully some news is coming
  • M
    Mario
    Shares of Tenax rose after the company reported progress in a phase 2 study of levosimendan for the treatment of pulmonary hypertension and heart failure.
    Bullish
  • C
    Colin
    This is what Armistice sees for the reason of getting on the boat.
    "The positive outcome of this Phase 2 trial represents a major milestone for Tenax and our development of levosimendan for the treatment of patients suffering from this debilitating illness,” stated Anthony DiTonno, Chief Executive Officer of Tenax. "It is particularly exciting to report these positive results that support our confidence that levosimendan’s unique pharmacologic profile and mechanism of action may be ideally suited to treat PH-HFpEF. We believe these results support a Phase 3 trial that will translate into the first approved therapy to treat these patients.”